Date of Award

6-2019

Document Type

Dissertation

Degree Name

Doctor of Philosophy (PhD)

Program

Pharmaceutical Sciences

Track

Pharmaceutics

Research Advisor

Santosh Kumar, Ph.D.

Committee

Chandravanu Dash, Wei Li, Bernd Meibohm, Charles R. Yates

Abstract

Cytochrome P450 2E1 (CYP2E1)-mediated hepatic and extra-hepatic toxicity is of significant clinical importance. Diallyl sulfide (DAS) has been shown to prevent xenobiotics such as alcohol- (ALC/ETH), acetaminophen- (APAP) induced toxicity and disease (e.g. HIV-1) pathogenesis. DAS imparts its beneficial effect by inhibiting CYP2E1-mediated metabolism of xenobiotics, especially at high concentration. However, DAS also causes toxicity at relatively high dosages and with long exposure times. The objective of the first project was to find potent DAS analogs which can replace DAS as a research tool or as potential adjuvant therapy in CYP2E1-mediated pathologies.

Declaration of Authorship

Declaration of Authorship is included in the supplemental files.

ORCID

0000-0002-5589-0114

DOI

10.21007/etd.cghs.2019.0474

2019-015-Rahman-DOA.pdf (417 kB)
Declaration of Authorship

Share

COinS